transplant vs surgery for early hcc
play

Transplant vs. Surgery for Early HCC Rajesh Ramanathan, MD Surgical - PowerPoint PPT Presentation

Transplant vs. Surgery for Early HCC Rajesh Ramanathan, MD Surgical Oncology ISIGO October 10 th , 2019 HPI 56yo with NAFLD undergoing HCC surveillance with AFP elevation to 22. HBV and HCV negative. CT scan with 1.3 cm hepatic dome


  1. Transplant vs. Surgery for Early HCC Rajesh Ramanathan, MD Surgical Oncology ISIGO October 10 th , 2019

  2. HPI • 56yo with NAFLD undergoing HCC surveillance with AFP elevation to 22. HBV and HCV negative. • CT scan with 1.3 cm hepatic dome hyperenhancing lesion without washout 1.3cm. LiRADS 3.

  3. HPI F/u MRI with two LiRADS 4 lesions: 1.3 x 1.2cm Segment 8 & 1.4 x 1.2 Segment 4A/B

  4. What would you do? a) PET/CT scan b) Biopsy one lesion c) Biopsy both lesions d) PET and Biopsy e) Neither

  5. What treatment would you suggest? What treatment would you suggest? (AFP: 26.4, PLT: 137, INR: 1.2, TBILI: 0.8, ALB: 4.6) a) Transplant referral b) Resection c) Ablation d) TACE e) Y90 f) Something else

  6. Tumor board recommendation Segment 4 lesion too deep to be resected. Ablation and Transplant evaluation recommended Patient not interested in transplantation due to lifelong immunosuppression Laparoscopic biopsy and ablation to both lesions performed (Bx: Moderately differentiated HCC)

  7. Follow-up 5 months later MRI with area of arterial hyperenhancement in the posterior aspect of the Segment 4 ablation site AFP 38

  8. What would you do next? Summary: Two lesions treated with two RFAs. Local recurrence at the segment 4 RFA site within 5 months. a) Liver resection b) Repeat ablation c) TACE d) Y90 e) Sorafenib

  9. Tumor board recommendation Patient now open to transplantation TACE performed as a bridge to transplant

  10. Transplant waitlist 14 months after diagnosis and 8 months after TACE: Three new LiRADS 4 lesions and progression of recurrence.

  11. Transplant waitlist 2 months later, AFP 602 & continued increase in bilobar lesions Referred for Y90 and lenvatinib (REFLECT)

  12. Summary 0 months: Diagnosed with HCC 2 months: RFA x2 7 months: Recurrence 9 months: TACE and transplant evaluation 12 months: Transplant approval and listing (no HCC exception) 14 months: Progression, not candidate Was this a missed opportunity for earlier transplant listing and approval?

  13. Thank you Rajesh Ramanathan MD Surgical Oncology Banner MD Anderson Cancer Center Rajesh.Ramanathan@bannerhealth.com (217) 721 1495

Recommend


More recommend